Skip to main content
About Us > Jerome D. Hamilton, Jr.
opentherapeutics-about-team-member-jerome

Jerome D. Hamilton, Jr.

Chief Business Officer

Jerome D. Hamilton, Jr. is Chief Business Officer (CBO) of Open Therapeutics. In this role, he is able to spend more focused time to follow his passion of educating both the scientific and investment community on the importance of scientific collaboration free of constraints.  He also enjoys excelling in articulating the strategic plan and value proposition of Open Therapeutics, particularly the Company’s exciting blockchain integration into open science.

Prior to his role as CBO, he was the CEO of Open Therapeutics.  He built the Company’s investor base and led strategic partnerships and oversaw team formation.  Under his leadership, the Therapoid platform moved from prototype to alpha version.

Prior to Open Therapeutics, Jerome was the Senior Vice President of Global Operations at Stratasys where he focused on ensuring Global Operations supported aggressive corporate growth from both a strategic and tactical perspective. Prior to Stratasys, he was Vice President at 3M where he devised strategic and operational plans for 3M’s Industrial Business Group. He was also the leader of the company’s Masking and Surface Protection Business with full P&L responsibilities. Hamilton also has extensive experience in Lean Six Sigma Operations, Corporate Quality and Acquisition Integration.  Prior to 3M, he was plant manager at Ford Motor Company where he reversed declining productivity at one facility, making it the top-ranked plant among twenty Ford plants.

Hamilton earned his Bachelor of General Science from Morehouse College, a Bachelor of Science in Industrial Engineering from Georgia Tech, and a Master of Science in Engineering Management from the University of Detroit Mercy. He also holds a Master of Science in International Logistics from Georgia Tech and has completed the Harvard Business School’s Advanced Management Program.

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange